This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stock Under $10 that he thinks could potentially double or triple in the next 6 to 12-months. See what he's trading today with a 14-day FREE pass.

Big-Cap Health Care Winners

NEW YORK (Real Money) -- A couple times a week, I check my sector scans to get a sense of which are home to the largest number of top-performing stocks. For the past several weeks, the number of companies from the health care sector has far outweighed the runner-up consumer sector.

Earlier this week, I wrote about a couple of smaller stocks with charts showing some potential, but the leaders run the gamut when it comes to market cap.

One longtime standout that remains a winner is Alexion Pharmaceuticals (ALXN), which is up 30% so far this year. Between July and March, the stock notched gains every month. It's not surprising to see the shares finally in consolidation mode, having pulled back from their March 23 all-time high of $95.01.

This is another example of a recent theme in the market -- that is, winners being rewarded. Alexion only corrected 15% from its high and, as of Thursday's close, after regaining some lost ground, was trading about 2% below its peak. It's currently hovering above its short-term five-day exponential moving average.

Thursday's heavy-volume price gains on the major indices were encouraging from a technical standpoint (no comment on the global macro implications) but still not enough to confirm a new uptrend, particularly in an environment where news from Europe can drag stocks back down in a heartbeat.

Alexion would be in a buy zone in a confirmed market uptrend. I continue to like the prospects for this stock, but with the whipsaw market action still very much present, the risk profile remains too high for new buys.

The maker of treatments for autoimmune disorders and other conditions is expected to report its second quarter in July. Analysts have pegged earnings at $0.37 per share on revenue of $262.05 million, which would mark a gain of 28% on the bottom line and 41% on the top line, for a continuation of the trend of double-digit gains in both categories.

Another big-cap leader that has been correcting is Intuitive Surgical (ISRG), a maker of robotic surgical devices.

Here, the 2012 gain is 14%. The stock was climbing at a solid rate in the early months of this year, but corrected 9.5% in May.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
DOW 16,982.59 +22.02 0.13%
S&P 500 1,978.91 +0.57 0.03%
NASDAQ 4,444.9090 -4.6550 -0.10%

Our Tweets

Brokerage Partners

Top Rated Stocks Top Rated Funds Top Rated ETFs